Donaldson Completes Acquisition of 49% Minority Stake in Medica S.p.A.
Donaldson Company, Inc. (NYSE: DCI) has completed its acquisition of a 49% minority stake in Medica S.p.A., a leader in hollow fiber membrane filtration technology, for approximately €62 million. This strategic move aligns with Donaldson's goal of expanding its Life Sciences business. Medica, headquartered in Medolla, Italy, specializes in medical device applications and water purification. With over 700 employees globally, Medica generated €80 million in revenue in 2023. This acquisition is expected to enhance Donaldson's capabilities in the filtration industry and strengthen its position in the life sciences sector.
Donaldson Company, Inc. (NYSE: DCI) ha completato l'acquisizione di una partecipazione di minoranza del 49% in Medica S.p.A., leader nella tecnologia di filtrazione a membrana in fibra cava, per un importo di circa 62 milioni di euro. Questa mossa strategica si allinea con l'obiettivo di Donaldson di espandere il proprio business delle scienze della vita. Medica, con sede a Medolla, Italia, è specializzata in applicazioni per dispositivi medici e depurazione dell'acqua. Con oltre 700 dipendenti a livello globale, Medica ha generato 80 milioni di euro di fatturato nel 2023. Si prevede che questa acquisizione migliori le capacità di Donaldson nel settore della filtrazione e rafforzi la sua posizione nel settore delle scienze della vita.
Donaldson Company, Inc. (NYSE: DCI) ha completado la adquisición de una participación minoritaria del 49% en Medica S.p.A., líder en tecnología de filtración de membrana de fibra hueca, por aproximadamente 62 millones de euros. Este movimiento estratégico se alinea con el objetivo de Donaldson de expandir su negocio de ciencias de la vida. Medica, con sede en Medolla, Italia, se especializa en aplicaciones de dispositivos médicos y purificación de agua. Con más de 700 empleados a nivel mundial, Medica generó 80 millones de euros en ingresos en 2023. Se espera que esta adquisición mejore las capacidades de Donaldson en la industria de filtración y fortalezca su posición en el sector de ciencias de la vida.
도널드슨 컴퍼니 주식회사 (NYSE: DCI)는 약 6200만 유로에 Medica S.p.A.의 49% 소수 지분을 인수했다고 발표했습니다. 이는 섬유 중공막 필터링 기술의 선두주자입니다. 이 전략적 결정은 도널드슨의 생명 과학 사업 확장 목표에 부합합니다. 이탈리아 메도라에 본사를 둔 Medica는 의료기기 응용 및 수질 정화에 특화되어 있습니다. Medica는 전 세계적으로 700명 이상의 직원을 두고 있으며, 2023년에 8천만 유로의 매출을 올렸습니다. 이번 인수는 도널드슨이 필터링 산업에서의 능력을 향상시키고 생명 과학 분야에서의 위치를 강화할 것으로 예상됩니다.
Donaldson Company, Inc. (NYSE: DCI) a finalisé l'acquisition d'une participation minoritaire de 49% dans Medica S.p.A., un leader de la technologie de filtration par membrane en fibre creuse, pour environ 62 millions d'euros. Cette stratégie s'inscrit dans l'objectif de Donaldson d'élargir son activité en sciences de la vie. Medica, dont le siège est à Medolla, en Italie, est spécialisée dans les applications de dispositifs médicaux et la purification de l'eau. Avec plus de 700 employés dans le monde, Medica a réalisé un chiffre d'affaires de 80 millions d'euros en 2023. Cette acquisition devrait renforcer les capacités de Donaldson dans le secteur de la filtration et consolider sa position dans le domaine des sciences de la vie.
Die Donaldson Company, Inc. (NYSE: DCI) hat ihre Übernahme von 49% der Minderheitsbeteiligung an der Medica S.p.A., einem führenden Unternehmen in der Technologie der hohlen Faser-Membranfiltration, für etwa 62 Millionen Euro abgeschlossen. Dieser strategische Schritt steht im Einklang mit Donaldsons Ziel, sein Lebenswissenschaftssegment auszubauen. Medica hat seinen Hauptsitz in Medolla, Italien, und ist auf medizinische Geräteanwendungen und Wasseraufbereitung spezialisiert. Mit über 700 Mitarbeitern weltweit erzielte Medica im Jahr 2023 einen Umsatz von 80 Millionen Euro. Diese Akquisition wird voraussichtlich die Fähigkeiten von Donaldson in der Filtrationsindustrie verbessern und seine Position im Bereich der Lebenswissenschaften stärken.
- Strategic expansion into the Life Sciences sector
- Acquisition of 49% stake in a company with €80 million annual revenue
- Access to advanced hollow fiber membrane filtration technology
- Potential for synergies in medical device and water purification markets
- Significant capital outlay of €62 million for a minority stake
- Potential integration challenges with partial ownership
Donaldson's acquisition of a 49% stake in Medica for
Medica's revenue of
Investors should monitor how this acquisition impacts Donaldson's financial performance and whether it leads to synergies or technology transfer between the two companies. The move into life sciences could potentially enhance Donaldson's long-term growth prospects, but integration and market penetration will be key factors to watch.
Donaldson's acquisition of a stake in Medica signifies a strategic entry into the high-growth medical device and water purification markets. Medica's expertise in hollow fiber membrane technology is particularly valuable, as this technology is important for various medical applications, including hemodialysis, plasma separation and cell therapy.
The life sciences sector, especially medical devices, offers significant growth potential due to aging populations and increasing healthcare demands globally. By partnering with Medica, Donaldson gains access to advanced filtration technologies that could lead to innovative product development and expansion in the healthcare sector.
This move could potentially accelerate Donaldson's R&D efforts in life sciences, leading to new product lines and market opportunities. However, success will depend on effective collaboration and leveraging of Medica's technological expertise within Donaldson's broader business strategy.
Medica is a leader in hollow fiber membrane filtration technology for medical device applications and water purification. Headquartered in Medolla,
More information can be found in the Donaldson press release dated April 29, 2024 and on the Company’s Investor Relations website at IR.Donaldson.com.
Statements in this release regarding future events and expectations, such as forecasts, plans, trends and projections relating to Donaldson’s business and financial performance, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and are identified by words or phrases such as “will likely result,” “are expected to,” “will continue,” “will allow,” “estimate,” “project,” “believe,” “expect,” “anticipate,” “forecast,” “plan” and similar expressions. These forward-looking statements speak only as of the date such statements are made and are subject to risks and uncertainties that could affect Donaldson’s performance and could cause Donaldson’s actual results for future periods to differ materially from any opinions or statements expressed. These factors include, but are not limited to, challenges in global operations; impacts of global economic, industrial and political conditions on product demand; impacts from unexpected events, including natural disasters; effects of unavailable raw materials or material cost inflation; inability to attract and retain qualified personnel; inability to meet customer demand; inability to maintain competitive advantages; threats from disruptive technologies; effects of highly competitive markets with pricing pressure; exposure to customer concentration in certain cyclical industries; inability to manage productivity improvements; inability to achieve commitments to ESG; results of execution of any acquisition, divestiture and other strategic transactions; vulnerabilities associated with information technology systems and security; inability to protect and enforce intellectual property rights; costs associated with governmental laws and regulations; impacts of foreign currency fluctuations; and effects of changes in capital and credit markets. These and other factors are described in Part I, Item 1A, “Risk Factors” of Donaldson’s Annual Report on Form 10-K for the fiscal year ended July 31, 2023. Donaldson undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, unless required by law. The results presented herein are preliminary, unaudited and subject to revision until Donaldson files its results with the United States Securities and Exchange Commission on Form 10-Q.
About Donaldson Company, Inc.
Founded in 1915, Donaldson (NYSE: DCI) is a global leader in technology-led filtration products and solutions, serving a broad range of industries and advanced markets. Diverse, skilled employees at over 140 locations on six continents partner with customers - from small business owners to R&D organizations and the world’s biggest OEM brands. Donaldson solves complex filtration challenges through three primary segments: Mobile Solutions, Industrial Solutions and Life Sciences. Additional information is available at www.Donaldson.com.
About Medica S.p.A
Medica Group has been operating since 1985 with its headquarters in the biomedical district of Mirandola,
View source version on businesswire.com: https://www.businesswire.com/news/home/20240812123000/en/
Sarika Dhadwal (952) 887-3753
Sarika.Dhadwal@Donaldson.com
Source: Donaldson Company, Inc.
FAQ
What is the value of Donaldson's acquisition of Medica S.p.A. stake?
How does the Medica acquisition align with Donaldson's strategy?
What was Medica S.p.A.'s revenue in 2023?
How many employees does Medica S.p.A. have globally?
